lesabelimab

Lesabelimab (BC-003) is a human monoclonal antibody targeting programmed death-ligand 1 (PD-L1), developed by Dragonboat Biopharmaceutical, a subsidiary of Guilin Sanjin Pharmaceutical. By binding to PD-L1, lesabelimab prevents its interaction with the PD-1 receptor on T cells, thereby inhibiting the immunosuppressive signaling that allows tumors to evade the immune system. It is currently under clinical investigation in Phase I and Phase II trials for the treatment of various advanced malignant solid tumors, including squamous cell carcinomas of the head and neck, esophagus, and penis, as well as lymphoma and several types of gynecological and urological cancers.

Other names

lesabelimab